Video Library
Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases
In this video, Prof. Deepak L. Bhatt presents an infographic on Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases – an overview of molecular functions and therapeutic strategies.
Prof. Deepak L. Bhatt
First published: September 10, 2024
Video Library
European Society of Cardiology (ESC) Congress highlights 2024
Video highlights from the European Society of Cardiology (ESC) Congress 2024, taking place in London from August 30 to September 2. Featuring faculty members Prof Stephen Nicholls, Prof Deepak Bhatt and Prof Yi-Heng Li, these clips provide invaluable insights and updates on cardiovascular research from ESC Congress 2024.
Prof Stephen Nicholls, Prof Yi-Heng Li
First published: August 30, 2024
Video Library
Therapeutic Management of Dyslipidaemia
In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the therapeutic management of dyslipidaemia. Dyslipidaemia, a key risk factor for cardiovascular diseases, is conventionally managed through therapies targeting lipoproteins such as LDL, Lp(a), IDL + VLDL through small-molecule therapeutics. Despite their effectiveness, off-target events and poor patient compliance often pose significant challenges. Hence novel therapeutics, such as small interfering RNAs, antisense oligonucleotides, and monoclonal antibodies have been developed. These advancements highlight a significant step forward in the management of dyslipidaemia. Prof. Cannon emphasizes these main points in the video, aiming to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.
Prof. Christopher Cannon
First published: August 1, 2024
Video Library
World Heart Federation Roadmap
In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the World Heart Foundation’s Cholesterol Roadmap (2022) for the management and prevention of atherosclerotic cardiovascular disease (ASCVD). He discusses various approaches for ASCVD prevention, emphasizes regional differences in adherence to ASCVD treatment guidelines, and highlights barriers to effective risk management. This roadmap offers a scientifically sound foundation for policymakers to implement changes aimed at reducing the burden of ASCVD.
Prof. Christopher Cannon
First published: August 1, 2024
Running time: 35 minutes, 49 seconds
00.16 Lp(a) structure and metabolism
01.51 Elevated Lp(a) prevalence and risk of cardiovascular diseases
02.38 Factors influencing Lp(a) level
03.35 Physiological functions of Lp(a)
04.12 Atherogenicity of Lp(a)
04.56 Clinical implication of Lp(a) elevation
05.25 Genetic variants associated with increased Lp(a) concentrations
05.44 Association between high Lp(a) level and risk of various cardiovascular diseases
07.43 Clinical implication of Lp(a) elevation at low LDL-C
08.47 Lp(a) categories increases absolute baseline risk of traditional risk factors
09.40 Is reducing Lp(a) physiologically safe?
10.34 Strategies to lower Lp(a) level
11.57 Future directions in Lp(a) research
12.37 Summary
Video Library
Lp(a):What is it and its role in atherosclerosis
In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.
Prof. S. Lale Tokgözoğlu
First published: March 11, 2024
Video Library
Lipid measurements in the management of cardiovascular diseases
In this video, Prof. Stephen Nicholls provides a comprehensive overview of our infographic on lipid measurements and their clinical implications, serving as a helpful resource for healthcare professionals involved in managing cardiovascular disease. Covering atherogenic dyslipidemia, lipid profile components, advanced tests, and genetic considerations, Prof. Nicholls emphasizes individualized approaches to interpreting lipid parameters based on patient demographics and risk levels. This aims to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.
First published: March 6, 2024
Running time: 58 minutes, 46 seconds
01.28 Concept of cumulated LDL exposure (mg-years)
05.11 Re-defining secondary prevention
08.04 Early secondary prevention
11.27 Late secondary prevention (CHD)
19.17 Late secondary prevention (PAD)
20.15 Very late secondary prevention (ACS)
23.18 Longer is better
24.55 Earlier is better
26.21 Younger is better
28.39 Older Adults also deserve treatment
41.12 Audience Q&A
Video Library
“Lower, Longer, Sooner, Earlier, and Younger”: Do we have enough evidence?
Prof. Chiang discusses Atherosclerotic Cardiovascular Disease (ASCVD) in context of cumulated LDL exposure, and the different stages of secondary prevention and how starting to manage the disease at a younger age or earlier stage is beneficial. At 41:12 he answers audience questions.
First published: October 25, 2023
Running time: 35 minutes, 49 seconds
00.00 Patients and plaque
03.30 Pictorial representation and
primary prevention or adherence07.00 Calcium Scoring
13.00 Other targets: Lp(a)
21.00 Triglycerides
28.00 Special: Latest data from ESC
Video Library
ASCVD Roundtable Part 2: Other targets and ESC 2023 Highlights
In this second part of the Round Table conversation, the Editorial Panel discuss how showing patients’ images of their plaques help with adherence, discuss other targets such as Lp (a) and triglycerides and most importantly, discuss some of the latest data from the recently concluded ESC congress.
Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt
First published: September 1, 2023
Running time: 25 minutes, 25 seconds
00.00 Introduction
01.21 LDL target and guidelines
07.55 Should we start combination
therapy early?12.35 Side effects of combination
therapy?16.40 Dosing in combination
therapy – InclisiranVideo Library
ASCVD Roundtable Part 1: Target guidelines, dosing, and compliance in lipid lowering therapies
In recognition of the ASCVD & Lipidology Knowledge Hub 2 year anniversary, the esteemed faculty members for this educational resource site met to discuss the hot topics that have occurred over this time. Come and take a seat at this roundtable discussion with Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, and Prof. Deepak Bhatt as they discuss target guidelines, dosing, and compliance in lipid lowering therapies.
Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt
First published: August 1, 2023